Current Status of Clozapine for Treatment-Resistant Schizophrenia / 대한정신분열병학회지
Korean Journal of Schizophrenia Research
; : 1-7, 2021.
Article
ي Ko
| WPRIM
| ID: wpr-902516
المكتبة المسؤولة:
WPRO
ABSTRACT
Clozapine is the first and most effective atypical antipsychotic drug for treatment-resistant schizophrenia (TRS). After withdrawal of clozapine due to concerns of agranulocytosis, clozapine was reintroduced with a comprehensive safety monitoring system, the clozapine patient monitoring system (CPMS). The reintroduction was a response to the pressure from psychiatrists and patients with TRS and their families. Clozapine is still the best single agent for the treatment of TRS. However, approximately 30% of patients with TRS still show psychotic symptoms. In patients with clozapine-resistant schizophrenia (CRS), augmentation of other antipsychotic agents could be considered after a thorough evaluation of proper clozapine treatment. In this review, the status of clozapine in patients with TRS and CRS will be discussed.
النص الكامل:
1
الفهرس:
WPRIM
اللغة:
Ko
مجلة:
Korean Journal of Schizophrenia Research
السنة:
2021
نوع:
Article